Skip to main content

Table 3 Effect of VigRX Plus on the IIEF domains

From: Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study

IIEF Domains

VigRX Plus

Placebo

 

Baseline

EoT

Change

95%CI

Baseline

EoT

Change

95%CI

EF,Q1-5,15

16.08 (2.87)

25.08 (4.56)*

9 (4.95)

7.40,10.60

15.86 (3.24)

16.47 (4.25)

0.61(2.43)

−0.21,1.43

Q1

3.38 (0.67)

4.64 (0.67)

1.26 (0.88)

0.98,1.54

3.33 (0.53)

3.38 (0.77)

0.06 (0.58)

−0.14,0.25

Q2

2.71(0.65)

4.17 (0.82)

1.46 (0.94)

1.16,1.76

2.66 (0.63)

2.80 (0.75)

0.14 (0.42)

−0.0,0.28

Q3

2.69 (0.57)

4.12 (0.80)

1.43 (0.85)

1.15,1.70

2.63 (0.59)

2.75 (0.69)

0.11(0.46)

−0.05,0.26

Q4

2.56 (0.50)

4.02 (0.81)

1.46 (0.91)

1.16, 1.76

2.44 (0.56)

2.66 (0.68)

0.22 (0.48)

0.06, 0.38

Q5

2.23 (0.78)

3.94 (0.89)

1.71 (1.02)

1.38, 2.04

2.27 (0.85)

2.33 (0.89)

0.06 (0.47)

−0.10, 0.21

Q15

2.48 (0.56)

4.15 (0.87)

1.66 (1.03)

1.33, 1.99

2.5 (0.56)

2.52 (0.84)

0.03 (0.56)

−0.16, 0.21

IS, Q6-8

7.28 (1.70)

11.58 (2.46)*

4.3 (2.47)

3.50,5.10

7.13 (1.76)

7.72(1.98)

0.58 (1.44)

0.09,1.07

OF, Q9-10

7.84 (0.93)9(

9.23 (1.13)*

1.38 (1.24)

0.98,1.78

7.77 (1.20)

7.77 (1.53)

0.0 (0.92)

−0.31,0.31

SD,Q11-12

6.35 (1.11)

9.05 (1.36)*

2.69 (1.73)

2.13,3.25

6.47 (1.28)

6.41 (1.5)

−0.05 (1.62)

−0.60,0.50

OS, Q13-14

5.46 (1.10)

8.17 (1.73)*

2.71 (1.86)

2.10,3.31

5.61 (0.96)

5.47 (1.50)

−0.14 (0.90)

−0.45,0.16

Total IIEF,Q1-15

42.56 (5.09)

63.13 (10.06)*

20.10 (11.08)

16.51,23.69

42.54 (5.10)

43.86 (8.45)

1.0 (5.73)

−0.93,2.93

  1. IIEF scores are expressed as Mean (SD), *P < 0.001 is statistically significant for change from baseline as compared to placebo.CI, confidence intervals; EF, erectile function; EoT, end of treatment; IS, intercourse satisfaction; OF, orgasmic function; OS, overall satisfaction; SD, sexual desire.